Literature DB >> 18337561

Novel HAX1 mutations in patients with severe congenital neutropenia reveal isoform-dependent genotype-phenotype associations.

Manuela Germeshausen1, Magda Grudzien, Cornelia Zeidler, Hengameh Abdollahpour, Sevgi Yetgin, Nima Rezaei, Matthias Ballmaier, Bodo Grimbacher, Karl Welte, Christoph Klein.   

Abstract

Homozygous mutations in HAX1 cause an autosomal recessive form of severe congenital neutropenia (CN). By screening 88 patients with CN, we identified 6 additional patients with HAX1 mutations carrying 4 novel mutations. Of these, 2 affect both published transcript variants of HAX1; the other 2 mutations affect only transcript variant 1. Analysis of the patients' genotypes and phenotypes revealed a striking correlation: Mutations affecting transcript variant 1 only were associated with CN (23 of 23 patients), whereas mutations affecting both transcript variants caused CN and neurologic symptoms, including epilepsy and neurodevelopmental delay (6 of 6 patients). In contrast to peripheral blood, transcript variant 2 was markedly expressed in human brain tissue. The clinical phenotype of HAX1 deficiency appears to depend on the localization of the mutation and their influence on the transcript variants. Therefore, our findings suggest that HAX1 isoforms may play a distinctive role in the neuronal system.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18337561     DOI: 10.1182/blood-2007-11-120667

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

1.  Kostmann disease with developmental delay in three patients.

Authors:  Caner Aytekin; Manuela Germeshausen; Nilden Tuygun; Gonul Tanir; Figen Dogu; Aydan Ikinciogullari
Journal:  Eur J Pediatr       Date:  2010-02-23       Impact factor: 3.183

Review 2.  Genetic and molecular diagnosis of severe congenital neutropenia.

Authors:  Alister C Ward; David C Dale
Journal:  Curr Opin Hematol       Date:  2009-01       Impact factor: 3.284

3.  Genetic correction of HAX1 in induced pluripotent stem cells from a patient with severe congenital neutropenia improves defective granulopoiesis.

Authors:  Tatsuya Morishima; Ken-ichiro Watanabe; Akira Niwa; Hideyo Hirai; Satoshi Saida; Takayuki Tanaka; Itaru Kato; Katsutsugu Umeda; Hidefumi Hiramatsu; Megumu K Saito; Kousaku Matsubara; Souichi Adachi; Masao Kobayashi; Tatsutoshi Nakahata; Toshio Heike
Journal:  Haematologica       Date:  2013-08-23       Impact factor: 9.941

4.  Novel HAX1 gene mutations associated to neurodevelopment abnormalities in two Italian patients with severe congenital neutropenia.

Authors:  Marina Lanciotti; Stefania Indaco; Sonia Bonanomi; Tiziana Coliva; Elena Mastrodicasa; Gianluca Caridi; Michaela Calvillo; Carlo Dufour
Journal:  Haematologica       Date:  2010-01       Impact factor: 9.941

5.  Molecular basis of congenital neutropenia.

Authors:  Christoph Klein
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

6.  Digenic mutations in severe congenital neutropenia.

Authors:  Manuela Germeshausen; Cornelia Zeidler; Manfred Stuhrmann; Marina Lanciotti; Matthias Ballmaier; Karl Welte
Journal:  Haematologica       Date:  2010-03-10       Impact factor: 9.941

Review 7.  Severe congenital neutropenias.

Authors:  Julia Skokowa; David C Dale; Ivo P Touw; Cornelia Zeidler; Karl Welte
Journal:  Nat Rev Dis Primers       Date:  2017-06-08       Impact factor: 52.329

8.  Prevalence of mutations in ELANE, GFI1, HAX1, SBDS, WAS and G6PC3 in patients with severe congenital neutropenia.

Authors:  Jun Xia; Audrey A Bolyard; Elin Rodger; Steve Stein; Andrew A Aprikyan; David C Dale; Daniel C Link
Journal:  Br J Haematol       Date:  2009-09-22       Impact factor: 6.998

Review 9.  Kostmann's Disease and HCLS1-Associated Protein X-1 (HAX1).

Authors:  Christoph Klein
Journal:  J Clin Immunol       Date:  2016-12-10       Impact factor: 8.317

Review 10.  Genetic insights into congenital neutropenia.

Authors:  Christoph Klein; Karl Welte
Journal:  Clin Rev Allergy Immunol       Date:  2010-02       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.